Structure-based discovery of positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor as cognition enhancers. KU Leuven
Laboratory of Structural Neurobiology, Laboratory of Virology and Chemotherapy (Rega Institute), Toxicology and Pharmacology
The alpha7 nicotinic acetylcholine receptor (nAChR) has attracted considerable attention as an emerging therapeutic target for the treatment of neurological disorders associated with cognitive dysfunction, such as schizophrenia and Alzheimer's disease. Both of these diseases are associated with a decline in cognitive function for which there remains an unmet medical need. We will employ a structure-based drug discovery approach, which takes ...